Read by QxMD icon Read

radio iodine therapy

Johann-Martin Hempel, Roman Kloeckner, Sandra Krick, Daniel Pinto Dos Santos, Simin Schadmand-Fischer, Patrick Boeßert, Sotirios Bisdas, Matthias M Weber, Christian Fottner, Thomas J Musholt, Mathias Schreckenberger, Matthias Miederer
BACKGROUND: Suspected recurrence of thyroid carcinoma is a diagnostic challenge when findings of both a radio iodine whole body scan and ultrasound are negative. PET/CT and MRI have shown to be feasible for detection of recurrent disease. However, the added value of a consensus reading by the radiologist and the nuclear medicine physician, which has been deemed to be helpful in clinical routines, has not been investigated. This study aimed to investigate the impact of combined FDG-PET/ldCT and MRI on detection of locally recurrent TC and nodal metastases in high-risk patients with special focus on the value of the multidisciplinary consensus reading...
November 3, 2016: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
Raja N Mahesh, Pranay R Korpole, Ganesh Shetty, Handrashekar U Kudru, Shivashankara K Nagiri
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
Sangeetha Mohanakrishnan, Ganesh Hk, Radhamohan
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
W Zhou, L Zhang, W Zhan, S Jiang, Y Zhu, S Xu
AIM: To evaluate the efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) for recurrent papillary thyroid carcinomas (PTC) <15 mm in the neck. MATERIALS AND METHODS: A retrospective study was conducted in 21 patients with 27 recurrent PTC lesions who underwent PLA. The extent of ablation was assessed by contrast-enhanced ultrasonography (CEUS) after PLA. Measurement of the volume of tumour and serum thyroglobulin, and clinical evaluation were performed at 7 days, and 1, 3, 6, and 12 months, and every 6 months thereafter...
December 2016: Clinical Radiology
Vincent Atallah, Arnaud Hocquelet, Christine Do Cao, Slimane Zerdoud, Christelle De La Fouchardiere, Stéphane Bardet, Antoine Italiano, Anne Dierick-Galet, Nicolas Leduc, Françoise Bonichon, Sophie Leboulleux, Yann Godbert
BACKGROUND: The aim of this study was to evaluate the effectiveness of sunitinib in patients with progressive radioiodine refractory (RAIR) thyroid cancer (TC). MATERIALS AND METHODS: A multicentric retrospective analysis was performed of patients treated in six TUmeurs THYroïdiennes REFractaires participating centers. All patients with progressive RAIR TC who were treated with sunitinib outside a clinical trial between August 2007 and March 2015 were retrospectively and consecutively included...
August 2016: Thyroid: Official Journal of the American Thyroid Association
P Santhanam, H K Driscoll, P Venkatraman
OBJECTIVE: Diagnostic whole body scan (pre-therapy scan) with either I-123 or I-131 (radioactive isotopes of iodine) is performed to assess the extent of thyroid cancer especially distant metastasis prior to administering the therapeutic dose of I-131. Our aim of the following study was to determine the utility of the diagnostic pre-therapy scan in the management of differentiated thyroid cancer. MATERIALS AND METHODS: It was a case-control study carried out by retrospective chart review, of a randomly selected 100 patients with differentiated thyroid cancer who had followed in our community hospital over the course of 1 year...
January 2016: Indian Journal of Cancer
Zhaowei Meng, Xinghua Song
No abstract text is available yet for this article.
August 2016: Clinical Nuclear Medicine
Jun Shen, Sufen Wang, Xintong Zhao, Xuefei Shao, Xiaochun Jiang, Yi Dai, Shanshui Xu, Xianwen Pan
Three patients' medical history, clinical manifestation, imaging characteristic, therapy and prognosis of calvaria metastasis from follicular thyroid carcinoma (FTC) in our hospital were retrospectively analyzed by reviewing medical literature. In case one, the tumor in frontal bone and fossa orbital was total resected, no further treatment was performed, the patient gave up on therapy and died of extensive metastasis at 22 months after the initial operation. In case two, the tumor in parietal and occipital bone was total resected, the subtotal resection of bilateral thyroid gland and isthmus was performed and combined with therapy of Levothyroxine and (131)I radio-iodine therapy, no evidence of tumor recurrence at 30 months after the primary operation...
2015: International Journal of Clinical and Experimental Pathology
Petr Vlček, Dagmar Nováková, Jan Vejvalka, Jaroslav Zimák, Martin Křenek, Květuše Vošmiková, Svatopluk Smutný, Petr Bavor, Jaromír Astl, Jindřich Lukáš
INTRODUCTION: The incidence of well-differentiated low-risk thyroid cancer have increased globally over the last three decades. Thyroid cancer treatment relates to a suitable surgical procedure and the use of adjuvant radio-iodine therapy in selected patients. Evaluation of prognostic factors and risk stratification are critical for determining appropriate treatment. Survival of patients with low-risk thyroid cancer is excellent. Appropriate choice of medical treatment resulted in full recovery in most patients...
September 2015: Vnitr̆ní Lékar̆ství
László Pávics, Zsuzsanna Besenyi
After a brief historical overview, the basic concept of therapy with radionuclides is summarised. This is followed by a review of the physical and biological features of the different radiopharmaceuticals that are available. A clinical application of the different techniques commences with the treatment of differentiated thyroid cancer using radio-iodine. From the various bone-seeking radiopharmceuticals, we opted for the alpha-emitting 223-RaCl2 for treatment purposes. Due to the increasing prevalence of neuroendocrine tumors nowadays, somatostatin receptor and adrenerg analog radiotherapy are discussed...
September 2015: Magyar Onkologia
Faycal El Majdoub, Clemens Neudorfer, Tobias Blau, Martin Hellmich, Christian Bührle, Martina Deckert, Volker Sturm, Mohammad Maarouf
PURPOSE: We evaluated the treatment of oligodendroglial brain tumors with interstitial brachytherapy (IBT) using (125)iodine seeds ((125)I) and analyzed prognostic factors. PATIENTS AND METHODS: Between January 1991 and December 2010, 63 patients (median age 43.3 years, range 20.8-63.4 years) suffering from oligodendroglial brain tumors were treated with (125)I IBT either as primary, adjuvantly after incomplete resection, or as salvage therapy after tumor recurrence...
December 2015: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Shahbaz Ahmad Khan, Muhammad Saqib Khan, Muhammad Arif, Durr-e-Sabih, Muhammad Kashif Rahim, Israr Ahmad
OBJECTIVE: To determine the patterns of dose rate reduction in single and multiple radioiodine (I-131) therapies in cases of well differentiated thyroid cancer patients. STUDY DESIGN: Analytical series. PLACE AND DURATION OF STUDY: Department of Nuclear Medicine and Radiation Physics, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Multan, Pakistan, from December 2006 to December 2013. METHODOLOGY: Ninety three patients (167 therapies) with well differentiated thyroid cancer treated with different doses of I-131 as an in-patient were inducted...
July 2015: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
Lei Chen, Xiaoyan Zhong, Xuan Yi, Min Huang, Ping Ning, Teng Liu, Cuicui Ge, Zhifang Chai, Zhuang Liu, Kai Yang
Nano-graphene and its derivatives have attracted great attention in biomedicine, including their applications in cancer theranostics. In this work, we develop 131I labeled, polyethylene glycol (PEG) coated reduced nano-graphene oxide (RGO), obtaining 131I-RGO-PEG for nuclear imaging guided combined radiotherapy and photothermal therapy of cancer. Compared with free 131I, 131IRGO- PEG exhibits enhanced cellular uptake and thus improved radio-therapeutic efficacy against cancer cells. As revealed by gamma imaging, efficient tumor accumulation of 131I-RGO-PEG is observed after its intravenous injection...
October 2015: Biomaterials
Jianfei Huang, Qi Tang, Changjun Wang, Huixin Yu, Zhenqing Feng, Jin Zhu
Vascular endothelial growth factor receptor 2 (VEGFR2) is traditionally regarded as an important therapeutic target in a wide variety of malignancies, such as hepatocellular carcinoma (HCC). We previously generated a murine-human anti-VEGFR2 chimeric Fab (cFab), named FA8H1, which has the potential to treat VEGFR2-overexpressing solid tumors. Here, we investigated whether FA8H1 can be used as a carrier in molecularly targeted therapy in HCC xenograft models. FA8H1 was labeled with (131)I, and two HCC xenograft models were generated using BEL-7402 (high VEGFR2-expressing) and SMMC-7721 (low VEGFR2-expressing) cells, which were selected from five HCC cell lines...
May 29, 2015: Scientific Reports
R Lorenz, A Buck, C Reiners
UNLABELLED: The aim of this analysis was to collect and analyse Germany-wide data on the status and development of in-patient Nuclear Medicine therapy. The official hospital quality reports were to be used as the data source. METHODS: The reference reports from all hospitals in Germany with Nuclear Medicine therapy units, compiled by Gemeinsamer Bundesausschuss (G-BA) from the machine-usable XML data of the quality reports, were analysed for the years 2010 and 2012...
2015: Nuklearmedizin. Nuclear Medicine
Loredana De Pasquale, Dimitri Rabbiosi, Alessandro Bardazzi, Luca Autelitano, Giacomina Pierina Moro, Giorgio Ghilardi
UNLABELLED: Multidisciplinary approach to follicular thyroid carcinoma with giant mandibular and multiple sites metastases. Case report Metastatic tumors generally have poor prognosis, with short survival period and rarely indication to surgical treatment. In case of thyroid-differentiated cancer with distant metastases, prognosis is usually better, because of the possibility of treating metastasis by Radio Ablation by 131Iodine, after surgery. We report the case of a 65 years old woman, presenting with a giant mandibular metastasis from follicular thyroid carcinoma, originating from a cervico-mediastinal nonfunctioning goiter, with lung metastases...
November 2014: Annali Italiani di Chirurgia
Guofang Chen, Diana Nicula, Kostja Renko, Michael Derwahl
Sorafenib, a multikinase inhibitor has recently been approved for the treatment of radio-iodine refractory thyroid carcinoma. However, toxic side effects may lead to dose reduction. In the present study, we analyzed whether a combined therapy with metformin may allow a dose reduction of sorafenib without loss of effectiveness at the same time. In HTh74 anaplastic thyroid carcinoma (ATC) cells and its derived doxorubicin-resistant HTh74Rdox cell line, the growth inhibitory effect of sorafenib with or without metformin was investigated...
April 2015: Oncology Reports
U Abdulrezzak, A Tutus, I Isik, Y Kurt, M Kula
PURPOSE: To compare the results of postoperative I--131 remnant ablation therapy using a quantitative data in the low activity (1110 MBq) and standard dose (3700 MBq). PATIENTS AND METHODS: The study included two groups of patients with low risk differentiated thyroid cancer (DTC): Group L (low dose group) included 54 patients who were treated with 1110 MBq I--131 and Group S (standard dose group) included 61 patients treated with 3700 MBq. The postoperative thyroid remnants were assessed with the pretreatment thyroid uptake test (PTUT) and the whole body scans (WBS) were performed in the 7th day after the ablation treatment...
January 20, 2015: Quarterly Journal of Nuclear Medicine and Molecular Imaging
W Jentzen, M Richter, T D Poeppel, J Schmitz, W Brandau, A Bockisch, I Binse
AIM: A retrospective study using PET/CT imaging with 124I--labeled metaiodobenzylguanidine (124I--MIBG) was performed to estimate the (radiation) absorbed dose to the salivary glands in neuroendocrine cancer patients undergoing 131I--MIBG therapy and to compare these results with those in radioiodine (131I--iodide) therapy. METHODS: Twenty--seven patients received individual 124I--MIBG--PET/CT dosimetries, among whom 18 had not previously undergone any MIBG therapies (patient group before treatment) and 9 had already received MIBG therapies prior to the tracer dosimetries (patient group after treatment)...
January 8, 2015: Quarterly Journal of Nuclear Medicine and Molecular Imaging
S J E Rombouts, J A Vogel, H C van Santvoort, K P van Lienden, R van Hillegersberg, O R C Busch, M G H Besselink, I Q Molenaar
BACKGROUND: Locally advanced pancreatic cancer (LAPC) is associated with a very poor prognosis. Current palliative (radio)chemotherapy provides only a marginal survival benefit of 2-3 months. Several innovative local ablative therapies have been explored as new treatment options. This systematic review aims to provide an overview of the clinical outcomes of these ablative therapies. METHODS: A systematic search in PubMed, Embase and the Cochrane Library was performed to identify clinical studies, published before 1 June 2014, involving ablative therapies in LAPC...
February 2015: British Journal of Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"